Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain

Brean Capital Sees 'Significant Uptake' for Progenics' (PGNX) Oral Relistor

Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and $14 price target on Progenics Pharmaceuticals (NASDAQ: PGNX) after the company and Valeant announced FDA approval of oral Relistor for the treatment of OIC in chronic non-cancer pain patients.

Aschoff commented, "Even with direct competitor Movantik on... More

Oral Relistor Approval the First of Many Progenics Pharmaceuticals (PGNX) Drivers - Needham & Company

Needham & Company analyst Chad Messer reiterated a Buy rating and $11 price target on Progenics Pharmaceuticals (NASDAQ: PGNX) after the FDA approved oral Relistor. He called it the first of many upcoming drivers for the stock.

Messer commented, "PGNX shares are indicated up... More

Progenics Pharma (PGNX) Surges Over 20% as FDA Approval Oral RELISTOR

Progenics Pharma (NASDAQ: PGNX) is ramping 21% in pre-open trade Wednesday after the company and Valeant Pharmaceuticals (NYSE: VRX) announced that the FDA has approved RELISTOR Tablets for the treatment of opioid-induced constipation (OIC) in adults with chronic... More

Rodman & Renshaw Reiterates Buy Rating on Valeant (VRX)

Rodman & Renshaw reiterated a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $90. Comments following an FDA panel vote in favor of brodalumab approval.

"On July 19, 2016, an FDA advisory committee gave brodalumab, an investigational anti interleukin-17 (anti-IL-17) monoclonal antibody for moderate-to-severe plaque psoriasis, a unanimous 18-0 vote in favor of approval. The panel also recommended, as we anticipated, a safety... More

BTIG Positive on Progenics Pharma (PGNX) Following FDA Approval of RELISTOR as OIC Treatment (VRX)

BTIG affirms Progenics Pharmaceuticals (Nasdaq: PGNX) at Buy with a price target of $9 after Progenics and Valeant Pharma (NYSE: VRX)... More

Valeant (VRX) Pipeline Developments 'Positive', But In-Line with Expectations - BMO Capital

BMO Capital analyst Gary Nachman weighed in on Valeant Pharmaceuticals (NYSE: VRX) after an FDA advisory panel resulted in unanimous support for the approval of brodalumab for the treatment of moderate to severe plaque psoriasis. However, the majority of the panel (78%) supported additional risk... More